Demand for COVID-19 antiviral drug remdesivir is rising sharply in India, a top executive at drugmaker Cipla Ltd said on Monday, even as experts remain divided over its effectiveness.
Remdesivir was developed by U.S. drugmaker Gilead Sciences Inc, which cut its 2020 revenue forecast last month, citing lower-than-expected demand and difficulty in predicting sales of the treatment. Cipla is among several firms licensed to make and sell generic versions in developing nations.
Cipla's version, Cipremi, was commercially launched in July and costs just above $50 per 100 mg vial.
"From October onwards, (the company is) seeing very sharp increase in (remdesivir) monthly volumes ... there are no constraints on supplies now," Cipla's global chief financial officer, Kedar Upadhye, told Reuters.
He said the company had sold more than 300,000 vials of the drug across the country as of September.
Remdesivir has become the standard of care for patients hospitalised with severe COVID-19, with more than 50 countries including the United States approving its use.
But the World Health Organization (WHO) said last month that its global trial of COVID-19 therapies had found that remdesivir did not have a substantial effect on the length of patients' hospital stays or their chances of survival.
"In India, the protocols (on remdesivir) have not changed, and demand continues," Cipla's Upadhye said, adding that the company has also begun export of the drug to "a few countries" in the second quarter, without giving any other details.
Mumbai-based Cipla, which has already been supplying the drug to South Africa since July, posted a 41.2% rise in consolidated net profit on Friday for the quarter ended Sept. 30.
(This story has not been edited by NDTV staff and is auto-generated from a syndicated feed.)
Sanju Samson Scripts History As India Register Big Win Over South Africa In 1st T20I "Lock The Kit Bag Away...": Ricky Ponting Suggests Babar Azam To Take Virat Kohli's Way To Regain Form BCCI Unhappy With 2 Key Decisions In New Zealand Series. Details Of 6-Hour Scrutiny Reveal... Trump's Immigration Curbs To Impact Millions Of Indians, Their Children Elon Musk Replies To 'We Need Your Help Removing Trudeau' Post Video: Jimmy Kimmel Chokes Up During TV Show Monologue About Trump Win Will Fight In Politics Till My Last Breath: Ex-PM Deve Gowda Viral Video Shows Sterilization In UP Labour Room, Strict Action Ordered China Launches "Exile Route" Experience, Sparking Social Media Debate Track Latest News Live on NDTV.com and get news updates from India and around the world.